<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909530</url>
  </required_header>
  <id_info>
    <org_study_id>222/16</org_study_id>
    <nct_id>NCT02909530</nct_id>
  </id_info>
  <brief_title>Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses</brief_title>
  <official_title>Comparison Between the Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in Endoscopic Ultrasound-guided Fine Needle Biopsy of Solid Pancreatic Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) is a valid and recommended
      technique for tissue diagnosis of pancreatic masses. However, the diagnostic yield is with a
      sensitivity of 64%-95% and an accuracy of 78%-94% still very low. The EUS-FNB of pancreatic
      masses is usually performed with a 22-gauge biopsy needle. The small diameter of the needle
      is usually responsible for the low yield of tissue samples for histopathological examination.
      The 19-gauge needles help to overcome the limitations of a 22-gauge needle by acquiring a
      larger amount of cellular material. Thus, performing EUS-FNB with a 19-gauge needle can
      maximize tissue acquisition and sample adequacy, which is important for appropriate
      diagnosis. Contrariwise, the technical success rate for sample retrieval in patients with
      pancreatic head lesions is significantly lower using the 19-gauge compared to the 22-gauge
      needle. This is attributable to the technical difficulty to push the needle out of the
      endoscope in the duodenum. Since about 60% of pancreatic cancers are located in the head
      region, it is therefore particularly important to improve technical success in these cases.
      The new 19-gauge biopsy needle &quot;Olympus EZ Shot3 Plus&quot; is more flexible than common biopsy
      needles such as &quot;EZ Shot2&quot; and should therefore provide improved access to regions like
      pancreatic head. The aim of this multicenter prospective randomized crossover study is to
      compare those two needles during EUS-FNB of solid pancreatic masses.

      Therefore this study will enroll 40 patients in five German centers with solid pancreatic
      masses and consecutive indication for EUS-FNB. Both needles will be used in each patient
      following a predetermined random order.

      Primary endpoint is the correct histological diagnosis of the mass assessed by each needle.
      Technical failure is regarded as a negative histological diagnosis.

      Secondary endpoints include a comparison of technical failure using each needle, histological
      quality, duration of procedure and rate of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correct histological diagnosis of the mass assessed by each needle</measure>
    <time_frame>6 months</time_frame>
    <description>Correct histological diagnosis of the mass assessed by each needle compared to gold standard. Gold standard is primarily positive histology, followed by diagnosis made due to additional methods to assess for malignancy (ultrasound, CT, ERCP, surgically retrieved specimen).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>technical failure (inability to push the EUS-FNB needle out the endoscope to perform puncture)</measure>
    <time_frame>Day one</time_frame>
    <description>Number of failure to push the needle out of the endoscope to perform biopsy counted per needle type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histological quality of the specimen retrieved (visual analog scale)</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of histological Quality using visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histological quality of the specimen retrieved (over all satisfaction)</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of histological Quality using over all satisfaction (&quot;1&quot;&lt;&quot;2&quot;, &quot;1&quot;=&quot;2&quot;, &quot;1&quot;&gt;&quot;2&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of procedure</measure>
    <time_frame>Day one</time_frame>
    <description>time frame between Insertion and extraction of needle or failure to conduct FNB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Acquisition of immediate adverse events related to the procedure or adverse events in the following 24 hours surveillance period or reported delayed adverse events (over 24 hours) related to the procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>First pass EZ Shot 3Plus then EZ Shot 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First pass EZ Shot 2 then EZ Shot 3Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-FNB with EZ Shot 3Plus first</intervention_name>
    <description>Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.</description>
    <arm_group_label>First pass EZ Shot 3Plus then EZ Shot 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-FNB with EZ Shot 2 19G first</intervention_name>
    <description>Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.</description>
    <arm_group_label>First pass EZ Shot 2 then EZ Shot 3Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  solid pancreatic mass and consecutive indication for EUS-FNB

        Exclusion Criteria:

          -  incapacity to give informed consent

          -  Haemorrhagic disease, disorder of hemostasis and coagulation (PT &lt;60%, PTT&gt; 42 sec.
             and platelets &lt;60000/µL)

          -  oral anticoagulants

          -  dual antiplatelet therapy with thienopyridines (e.g. clopidogrel)

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Meining</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Meining</last_name>
    <phone>0049 731 500</phone>
    <phone_ext>44632</phone_ext>
    <email>alexander.meining@uniklinik-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Hann</last_name>
    <phone>0049 731 500</phone>
    <phone_ext>44750</phone_ext>
    <email>alexander.hann@uniklinik-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Israelitisches Krankenhaus Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Rosien</last_name>
      <phone>0049 40 51125</phone>
      <phone_ext>0</phone_ext>
      <email>u.rosien@ik-h.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Holweide der Stadt Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arno Dormann</last_name>
      <phone>0049 2 21 89 07</phone>
      <phone_ext>2602</phone_ext>
      <email>dormanna@kliniken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niel Stensen Kliniken Marienhospital Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Möschler</last_name>
      <phone>0049 541 326</phone>
      <phone_ext>8104</phone_ext>
      <email>oliver.moeschler@mho.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Bohle</last_name>
      <phone>0049 711 278</phone>
      <phone_ext>35125</phone_ext>
      <email>w.bohle@klinikum-stuttgart.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Meining</last_name>
      <phone>0049 731 500</phone>
      <phone_ext>44632</phone_ext>
      <email>alexander.meining@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>November 24, 2016</last_update_submitted>
  <last_update_submitted_qc>November 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Alexander Meining</investigator_full_name>
    <investigator_title>Prof. Dr. Alexander Meining</investigator_title>
  </responsible_party>
  <keyword>Endoscopic ultrasound-guided fine needle biopsy</keyword>
  <keyword>Olympus EZ Shot 3Plus</keyword>
  <keyword>Olympus EZ Shot 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

